» Articles » PMID: 24253338

The Special Role of Ultrasound for Screening, Staging and Surveillance of Malignant Ovarian Tumors: Distinction from Other Methods of Diagnostic Imaging

Overview
Date 2013 Nov 21
PMID 24253338
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Ovarian cancer is the most aggressive gynecologic malignancy, with a 5-year survival rate ranging around 40%. A crucial factor influencing the prognosis is early detection of a suspicious mass and referral to a gynecologic oncology center for further diagnosis, staging and debulking surgery. Here, we present the different imaging methods ultrasound (US), magnetic resonance imaging, computer tomography (CT) and 18F-fluoro-deoxyglucose positron emission tomography (PET)/CT that are used for the characterization, diagnosis, staging and surveillance of ovarian cancer. In this review, we focus on US and discuss in detail the advantages and the limitations, as well as the appropriate indications for each of the individual imaging techniques.

Citing Articles

A Novel Classifier Based on Urinary Proteomics for Distinguishing Between Benign and Malignant Ovarian Tumors.

Ni M, Zhou J, Zhu Z, Yuan J, Gong W, Zhu J Front Cell Dev Biol. 2021; 9:712196.

PMID: 34527671 PMC: 8437375. DOI: 10.3389/fcell.2021.712196.


Utility of Preoperative Inflammatory Markers to Distinguish Epithelial Ovarian Cancer from Benign Ovarian Masses.

Li L, Tian J, Zhang L, Liu L, Sheng C, Huang Y J Cancer. 2021; 12(9):2687-2693.

PMID: 33854628 PMC: 8040725. DOI: 10.7150/jca.51642.


Diagnostic accuracy of inflammatory markers for distinguishing malignant and benign ovarian masses.

Eo W, Kim K, Park E, Kim H, Kim H, Koh S J Cancer. 2018; 9(7):1165-1172.

PMID: 29675097 PMC: 5907664. DOI: 10.7150/jca.23606.


Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol.

Katapodi M, Viassolo V, Caiata-Zufferey M, Nikolaidis C, Buhrer-Landolt R, Buerki N JMIR Res Protoc. 2017; 6(9):e184.

PMID: 28931501 PMC: 5628286. DOI: 10.2196/resprot.8138.


Usefulness of the preoperative platelet count in the diagnosis of adnexal tumors.

Watrowski R, Heinze G, Jager C, Forster J, Zeillinger R Tumour Biol. 2016; 37(9):12079-12087.

PMID: 27207344 DOI: 10.1007/s13277-016-5090-2.